.Pharmacolibrary.Drugs.ATC.G.G04BD08

Information

Solifenacin is an antimuscarinic medication used primarily for the treatment of overactive bladder with symptoms of urinary frequency, urgency, and incontinence. It is an approved prescription drug and widely used in clinical practice to manage symptoms of urinary incontinence.

Pharmacokinetics

Reported pharmacokinetic parameters in healthy adult subjects after single oral administration.

References

1. Tannenbaum, S, et al., & Newgreen, D (2020). Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity. Pharmacology research & perspectives 8(6) e00684–None. DOI:10.1002/prp2.684 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33231929

2. Taekema-Roelvink, ME, et al., & Smulders, RA (2005). Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study. Clinical therapeutics 27(9) 1403–1410. DOI:10.1016/j.clinthera.2005.09.002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16291413

3. Abrams, P, & Andersson, KE (2007). Muscarinic receptor antagonists for overactive bladder. BJU international 100(5) 987–1006. DOI:10.1111/j.1464-410X.2007.07205.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/17922784

Revisions

• 06/2025 initial generated model